Screener
CytomX Therapeutics CTMX Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $1.42M-92.4% | $10.26M-79.9% | $663K-98.3% | $5.96M-82.2% | $18.66M-25.7% | ||
| $17.6M+32.1% | $19.24M+2.0% | $21.24M+43.6% | $15.3M-28.4% | $13.32M-47.1% | ||
| $7.6M+14.8% | $10.69M+13.4% | $7.36M+30.9% | $6.43M-19.2% | $6.62M-21.1% | ||
| $25.2M+26.3% | $29.93M+5.8% | $28.6M+40.1% | $21.73M-25.9% | $19.94M-40.6% | ||
| -$23.78M-1,749% | -$19.67M-187% | -$27.93M-258% | -$15.77M-484% | -$1.29M+84.8% | ||
| -1,677.1%-1,670pp | -191.8%-236pp | -4,213%-4,259pp | -264.4%-277pp | -6.9%+26.8pp | ||
| $18K+5.9% | -$7K-164% | —— | $5K+171% | $17K+950% | ||
| -$20.61M-22,544% | -$18.19M-177% | -$26.46M-240% | -$14.17M-344% | -$91K+98.6% | ||
| $60K-4.8% | $59K-4.8% | $54K-12.9% | $58K-4.9% | $63K+23.5% | ||
| -$20.67M-13,319% | -$18.25M-178% | -$26.51M-240% | -$14.23M-348% | -$154K+97.6% | ||
| -1,457.4%-1,457pp | -177.9%-224pp | -3,998.5%-4,048pp | -238.6%-256pp | -0.8%+25.2pp | ||
| -$23.75M-1,801% | -$19.64M-187% | -$27.9M-257% | -$15.73M-479% | -$1.25M+85.2% | ||
| -1,674.5%-1,668pp | -191.4%-236pp | -4,207.4%-4,254pp | -263.8%-276pp | -6.7%+26.8pp | ||
| -$23.78M-1,749% | -$19.67M-187% | -$27.93M-258% | -$15.77M-484% | -$1.29M+84.8% |
FAQ
- What is CytomX Therapeutics's revenue?
- CytomX Therapeutics (CTMX) generated $18.3M in revenue over the trailing twelve months, down 87.0% year over year.
- Is CytomX Therapeutics profitable?
- CytomX Therapeutics is not currently profitable: it reported a net loss of $79.7M over the trailing twelve months, a -435.2% net margin.
- What is CytomX Therapeutics's earnings per share?
- CytomX Therapeutics's diluted EPS over the trailing twelve months is $-0.50.
- Where does CytomX Therapeutics's income statement data come from?
- Every line is extracted from CytomX Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
